Company
Portfolio Data
Back to Company SearchEARLY ALZHEIMER'S DIAGNOSTICS LLC
Address
66 JEFFERSON RDGLENMONT, NY, 12077-3318
USA
UEI: VTM8N8JNRWR8
Number of Employees: 2
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
SBIR/STTR Involvement
Year of first award: 2022
2
Phase I Awards
0
Phase II Awards
N/A
Conversion Rate
$581,687
Phase I Dollars
$0
Phase II Dollars
$581,687
Total Awarded
Awards
STTR Phase I:Saliva Screening Test for Alzheimer’s Disease
Amount: $274,713 Topic: BM
The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project entails the development of a simple and affordable saliva-based test that will enable the detection of early Alzheimer's disease. Today, there is no single test that can determine if a person has Alzheimer's disease. Because the diagnosis is complex, invasive, and expensive, these tests are only performed once symptoms, such as memory loss, begin to manifest. These symptoms of Alzheimer's disease only become apparent once the disease has already cause significant damage to the brain. The proposed test will be widely accessible and detect the disease before symptoms arise, enabling the patient to start active prevention strategies and even therapies to preserve brain health. As the American population ages — nearly 1 in 4 Americans will be 65 years of age or older by 2060 — Alzheimer’s disease and other dementias are becoming a great challenge for health and social care. As part of a broad approach to prevention, this technology can potentially extend early Alzheimer’s care to millions of Americans, allowing interventions, monitoring, and treatment initiation years earlier than what is currently possible._x000D_ _x000D_ This Small Business Technology Transfer (STTR) Phase I project is applying sophisticated chemical analysis methods to develop a novel test to detect signs of early Alzheimer’s disease using a person’s saliva. Diseases can cause changes in the biochemical composition of body fluids such as blood or saliva. Using a modern, highly sensitive type of spectroscopy based on light scattering, and combining it with advanced statistical approaches (i.e., machine learning), this project is developing a method that can reliably detect biochemical changes in saliva specific to Alzheimer’s disease. This project aims to demonstrate the feasibility of the approach by showing its ability to distinguish saliva donated by healthy individuals from saliva collected from Alzheimer's patients at both mild and moderate stages of the disease. The project will also investigate whether known biomarkers for Alzheimer’s disease are being identified by this method and develop statistical approaches to interpret spectroscopic data._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Tagged as:
STTR
Phase I
2023
NSF
Screening for Alzheimer's Disease Based on Raman Spectroscopy of Blood
Amount: $306,974 Topic: NIA
Abstract - Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects an estimated 6.2 million Americans and the 6th leading cause of death in the U.S. AD is progressive and incurable; dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but in late-stage AD, individuals lose the ability to carry on a conversation and respond to their environment. AD is a devastating condition that creates vast emotional, financial, and physical challenges for the person and their family. In AD, pathological changes may arise up to 20 years before the onset of dementia, providing a unique window of opportunity for interventions aimed at preserving cognitive health and delaying disease progression. However, there is currently no diagnostic tool that can be widely applied for the detection of preclinical AD. When potentially effective therapies are initiated late in the underlying disease pathology process (i.e., after cognitive decline is apparent), the true impact of prevention is not achieved. In response to the critical need for an accessible diagnostic tool for early and preclinical AD, Early Alzheimer’s Diagnostics proposes to develop a screening technology based on Raman Spectroscopy combined with machine learning (ML) models trained to detect spectral signature changes based on the contribution of multiple biomarkers found in the blood. The proposed technology has the potential to greatly improve outcomes by allowing patients to identify early signs of AD, and therefore start preventive interventions and active monitoring of disease progression, delaying the onset of dementia, and preserving brain health for longer. Such a tool would also have significant utility in clinical trials for critically needed new AD therapies, facilitating recruitment and selection of healthy volunteers and AD patients at various stages of disease progression. Preliminary results show that the approach can differentiate the biochemical composition of blood from patients at different stages of AD from healthy controls. The team has also developed a novel method using automated mapping of solid samples to detect ultra-small amounts of biomarkers by preventing them from leaving a small volume interrogated by the focused laser light during spectral acquisition. This Phase I project will provide de-risk key aspects in the process of adapting the technology into a clinical commercial application and provide proof-of-feasibility via a blind test. The Specific Aims of this STTR project are: 1) Optimize a scalable, rapid methodology for obtaining and analyzing Raman spectral data from blood serum; 2) Develop ML algorithm approaches for analyzing Raman spectral data; and 3) Validate the Raman spectroscopy-based approach in a blind test. Successful completion of proposed research will position Early Alzheimer’s Diagnostics to perform initial clinical trials in Phase II, and advance discussions with potential industry partners to establish partnerships to develop the proposed approach into either a stand- alone diagnostic test or possible companion diagnostic.Narrative - Alzheimer’s disease is a progressive, incurable neurodegenerative disorder, and its pathology begins many years before symptoms emerge, underscoring the importance of early diagnostics. Early Alzheimer’s Diagnostics proposes to develop a Raman spectroscopy-based diagnostic tool for Alzheimer’s disease, based on a minimally invasive blood test. Early Alzheimer’s Diagnostics has the potential to dramatically improve outcomes by allowing patients to start treatment with disease-modifying therapies years earlier than what is currently possible.
Tagged as:
STTR
Phase I
2022
HHS
NIH